Journal
NATURE BIOTECHNOLOGY
Volume 28, Issue 1, Pages 79-U107Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.1599
Keywords
-
Categories
Funding
- American Heart Association [0735637N]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases [R21AR055712]
- National Institute of Allergy and Infectious Diseases [R01AI072176]
- National Heart, Lung, and Blood Institute [R01HL089221]
- Senator Paul Wellstone Center for Muscular Dystrophy [U54AR056953]
- National Institute of General Medical Sciences [R01GM082946]
Ask authors/readers for more resources
Reengineering the receptor footprints of adeno-associated virus (AAV) isolates may yield variants with improved properties for clinical applications. We generated a panel of synthetic AAV2 vectors by replacing a hexapeptide sequence in a previously identified heparan sulfate receptor footprint with corresponding residues from other AAV strains. This approach yielded several chimeric capsids displaying systemic tropism after intravenous administration in mice. Of particular interest, an AAV2/AAV8 chimera designated AAV2i8 displayed an altered antigenic profile, readily traversed the blood vasculature, and selectively transduced cardiac and whole-body skeletal muscle tissues with high efficiency. Unlike other AAV serotypes, which are preferentially sequestered in the liver, AAV2i8 showed markedly reduced hepatic tropism. These features of AAV2i8 suggest that it is well suited to translational studies in gene therapy of musculoskeletal disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available